WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 462362
Description: MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor with anti-angiogenesis and anti-cancer activity. MYLS22 inhibits angiogenesis and tumor growth and metastatization, by impinging on NFkB activity and on angiogenic gene expression. In addition, MYLS22 causes tumor growth curtailed mice with 10 mg/kg/die.
MedKoo Cat#: 462362
Chemical Formula: C24H21N5O2S
Exact Mass: 443.1416
Molecular Weight: 443.525
Elemental Analysis: C, 64.99; H, 4.77; N, 15.79; O, 7.21; S, 7.23
Synonym: MYLS22; MYLS-22; MYLS 22
IUPAC/Chemical Name: N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-methyl-1-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxamide
InChi Key: WIEJADKUYLLKPX-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H21N5O2S/c1-15-19-14-20(32-24(19)28(26-15)17-10-6-4-7-11-17)22(30)25-21-16(2)27(3)29(23(21)31)18-12-8-5-9-13-18/h4-14H,1-3H3,(H,25,30)
SMILES Code: O=C(C(S1)=CC2=C1N(C3=CC=CC=C3)N=C2C)NC4=C(C)N(C)N(C5=CC=CC=C5)C4=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 443.525 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Herkenne S, Ek O, Zamberlan M, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020;31(5):987-1003.e8. doi:10.1016/j.cmet.2020.04.007